In this study, we assessed the impact of inherited variants in ABCB1, ABCG2, PXR, and CAR genes on dasatinib efficacy and toxicity in CML. This evidence concerns the gene NR1I3 and chronic myelogenous leukemia, BCR-ABL1 positive.